Any current/future new fundraising through debt or equity?

Suraksha Diagnostic Limited plans a capex of around INR 70 crores for FY26. The company does not currently require any debt for this capex and intends to use internal accruals. If needed, the company may consider equipment financing, but no specific debt fundraising is planned. The company is open to exploring inorganic growth opportunities, including acquisitions, mainly in Eastern India and West Bengal. There is no mention of any current or planned equity fundraising in the provided information.

Any current/future capex/capital investment/strategic investment?

Planned capex for FY26 is around INR 70 crores. No requirement for debt financing for this capex; internal accruals will fund it. Equipment financing may be considered if needed. Additional investment around INR 22 crores has been made to establish a state-of-the-art genomics lab. Future plans include further investment of around INR 45 crores in genomics over the next two years. The company is actively exploring both organic and inorganic growth opportunities, especially in East India and nearby states including West Bengal. Focus on expanding advanced services like genomics, fetal medicine,

Future growth expectations in sales/revenue/volumes?

Revenue growth guidance for FY26 is targeted at 15%. Volume growth is expected but hard to quantify precisely due to variability in test packages and parameters. Addition of B2B business, especially package-oriented corporate sales, is driving volume growth. Expansion plans include adding 15 to 18 new centers in FY26, contributing to overall volume and revenue growth. Mature centers maintain strong EBITDA margins (~37%), newer centers have potential to improve as they mature. Focus on genomics and molecular testing as a key growth driver, targeting cumulative incremental revenue of INR40-45 cr

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue growth guidance for FY26 is targeted at 15%. EBITDA margin guidance for FY26 is around 34%–35%. EBITDA margins for mature centers (older than 2 years) currently stand at ~37%, indicating potential for margin expansion as new centers mature. Volume growth is expected but is difficult to quantify precisely due to variability in test packaging and parameters. Addition of 15 to 18 new centers planned in FY26 will initially put pressure on margins, but economies of scale and operating leverage are expected to improve profitability over time. Genomics and fetal medicine verticals a

Suraksha Diagnostic LtdQ1 FY26Healthcare Services

Suraksha Diagnostic Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹298P/E: 43.4Market Cap: ₹1.6K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Revenue growth guidance for FY26 is targeted at 15%.
Volume growth is expected but hard to quantify precisely due to variability in test packages and parameters.
Addition of B2B business, especially package-oriented corporate sales, is driving volume growth.
Expansion plans include adding 15 to 18 new centers in FY26, contributing to overall volume and revenue growth.
Mature centers maintain strong EBITDA margins (~37%), newer centers have potential to improve as they mature.
Focus on genomics and molecular testing as a key growth driver, targeting cumulative incremental revenue of INR40-45 crores over two years.
Strategic foray into pillared business verticals like fetal medicine with Fetomat acquisition and genomics lab to increase service range and market share.
Overall growth expected to be fueled by both organic center expansion and B2B partnerships.

Margin guidance

Category 3

Revenue growth guidance for FY26 is targeted at 15%.
EBITDA margin guidance for FY26 is around 34%–35%.
EBITDA margins for mature centers (older than 2 years) currently stand at ~37%, indicating potential for margin expansion as new centers mature.
Volume growth is expected but is difficult to quantify precisely due to variability in test packaging and parameters.
Addition of 15 to 18 new centers planned in FY26 will initially put pressure on margins, but economies of scale and operating leverage are expected to improve profitability over time.
Genomics and fetal medicine verticals are key growth drivers; INR22 crore has been invested with expectation of cumulative incremental revenue of INR40–45 crore over two years.
Margin improvements expected as newly added centers stabilize and scale, with long-term aim to reach 100 centers.
No significant margin decline anticipated despite aggressive expansion due to cost management.

See what Suraksha Diagnostic Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Suraksha Diagnostic Limited plans a capex of around INR 70 crores for FY26.
The company does not currently require any debt for this capex and intends to use internal accruals.
If needed, the company may consider equipment financing, but no specific debt fundraising is planned.
The company is open to exploring inorganic growth opportunities, including acquisitions, mainly in Eastern India and West Bengal.
There is no mention of any current or planned equity fundraising in the provided information.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Suraksha Diagnostic Limited. However, the following relevant points provide some insight into business outlook and growth plans: - The company is focused on expanding its center network, targeting 15 to 18 new centers in FY26, with some closures of smaller collection points. - They plan to grow their B2B partnerships, especially in genomics and corporate segments, with signed MOUs indicative of pipeline growth. - Capex of around INR 70 crores is planned for expansion and setting up new labs without incurring significant debt. - Revenue growth guidance for FY26 is approximately 15%, with an EBITDA margin target of 34-35%. - The acquisition of Fetomat Wellness expands capability in genomic medicine and women's healthcare, opening new revenue channels. - They are entering genomics vertical — expecting incremental cumulative revenue of INR 40-45 crores over two years. No specific order backlog numbers are disclosed in the available transcript.

See what Suraksha Diagnostic Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Planned capex for FY26 is around INR 70 crores.
No requirement for debt financing for this capex; internal accruals will fund it.
Equipment financing may be considered if needed.
Additional investment around INR 22 crores has been made to establish a state-of-the-art genomics lab.
Future plans include further investment of around INR 45 crores in genomics over the next two years.
The company is actively exploring both organic and inorganic growth opportunities, especially in East India and nearby states including West Bengal.
Focus on expanding advanced services like genomics, fetal medicine, and molecular testing.
Strategic investments include the acquisition of a 63% stake in Fetomat Wellness Pvt Ltd, enhancing prenatal diagnostics and genomic service capabilities.

Track Suraksha Diagnostic Ltd — get its next earnings analysis in your feed

How does Suraksha Diagnostic Ltd rank vs peers in Healthcare Services?

Pro feature

ThisSuraksha Diagnostic Ltd

Rev 3Mar 3

See where Suraksha Diagnostic Ltd sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Suraksha Diagnostic Ltd rank in Healthcare Services?

Compare Suraksha Diagnostic Ltd against every Healthcare Services company (Q1 FY26) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Suraksha Diagnostic Ltd's management said in earlier quarters

Others in Healthcare Services this season

Aatmaj Healthcare Ltd (Q1 FY27)
Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again
Maitreya Medica. (Q2 FY26)
23.92 crore (Page 26). Key investor presentation takeaways from Maitreya Medica.'s Q2 FY26 investor presentation — and how it ranks against sector peers.
Metropolis Healt (Q2 FY26)
Organic growth remains strong at around 12%, with no immediate price hikes planned. Key concall takeaways from Metropolis Healt's Q2 FY26 earnings call — and…
Suven Life Scie. (Q4 FY26)
The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. Key investor presentation takeaways from Su

Compare:vs Apollo Hospitals Enterprise Ltd vs Manipal Health Enterprises Ltd vs Max Healthcare Institute Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Suraksha Diagnostic Ltd Q1 FY26 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Suraksha Diagnostic Ltd rank in Healthcare Services?

Continue your research

What Suraksha Diagnostic Ltd's management said in earlier quarters

Others in Healthcare Services this season